venBio Partners LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001776382

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 7 positions · Total reported value $519.38M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 50.0% · 2 new · 1 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +22.0% · vs SPY +7.2% · Prev Value $280.55M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, venBio Partners LLC disclosed 7 equity positions with a combined reported value of $519.38M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were PHVS ($160.57M), PBLS ($144.15M), ALMS ($127.43M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, venBio Partners LLC opened 2 new positions, trimmed 1 and fully exited 1, a turnover rate of 50.0% of positions. The portfolio's overlap with the prior quarter was 62% of names.

The largest new positions opened in Q2 2026 were PBLS ($144.15M), ACHV ($38.62M).

Of the 1 positions fully exited versus the prior quarter, the largest were ARTV ($3.42M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • PBLS PARABILIS MEDICINES INC · $144.15M
  • ACHV ACHIEVE LIFE SCIENCES INC · $38.62M

Fully Exited (vs previous quarter)

  • ARTV ARTIVA BIOTHERAPEUTICS INC · prev qtr: $3.42M

Insider Transactions (Form 4)

Latest venBio Partners LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

venBio Partners LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 7 US equity positions with a combined value of $519.38M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 7 positions · $519.38M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: PHVS (PHARVARIS N V) at 30.9%
  • Average position size: $74.20M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 2 new, 1 reduced, 1 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautious stance, with a slight increase in positions but no significant shifts in sector allocation. The focus on biotech and healthcare companies suggests a belief in the growth potential of these sectors. 2. Key Moves: - Added: Parabalis Medicines (PBLS) and Achieve Life Science (ACHV). Both additions are in the healthcare sector, indicating a continued interest in biotech. - Reduced: Harmony Biosciences (HRMY) with a reduction of 3.5% in shares, suggesting a reevaluation of the company's prospects or a shift in focus within the healthcare sector. 3. Portfolio Structure: - Passive/Active: The portfolio seems to be active, as it is adjusting positions and adding new holdings. - Sector Bias: The fund has a strong bias towards healthcare, particularly biotech, with seven out of ten holdings in this sector. - Risk Appetite: The risk appetite is moderate, with a balanced approach to adding new positions and maintaining existing ones. 4. Per-Holding One-Liner: - PHARVARIS N V (PHVS): A biotech company focused on developing treatments for rare genetic diseases. - PARABILIS MEDICINES INC COM (PBLS): A biotech company developing novel therapies for cancer and other diseases. - ALUMIS INC (ALMS): A biotech company focused on developing treatments for rare genetic diseases. - ACHIEVE LIFE SCIENCE INC (ACHV): A biotech company focused on developing treatments for rare genetic diseases. - ALX ONCOLOGY HLDGS INC (ALXO): A biotech company focused on developing treatments for cancer. - HARMONY BIOSCIENCES HLDGS IN (HRMY): A biotech company focused on developing treatments for neurological and psychiatric disorders. - LYELL IMMUNOPHARMA INC (LYEL): A biotech company focused on developing treatments for autoimmune diseases. 5. One-Sentence Style Summary: venBio Partners LLC maintained a cautious yet proactive approach in Q2 2026, focusing on biotech and healthcare sectors, adding new positions while slightly reducing exposure to Harmony Biosciences.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 4.64M $160.57M 30.92%
30.92%
Hold
2 5.27M $144.15M 27.75%
27.75%
New
3 4.53M $127.43M 24.54%
24.54%
Hold
4 5.91M $38.62M 7.44%
7.44%
New
5 12.88M $26.67M 5.13%
5.13%
Hold
6 472.19K $17.19M 3.31%
3.31%
Reduce
7 337.70K $4.74M 0.91%
0.91%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 83% R 71% F1 77% (modelled on 2026-Q1; 5/10 hit)

Historical Backtest (10 quarters)

Avg precision 92% · recall 92% · F1 92% · avg rank error 1.6 · Top-10 turnover 8%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 71% 100% 83% RYZB · ALXO · PHVS · HRMY · SLRN · ELEV · IMPLQ ALXO · PHVS · HRMY · SLRN · ELEV
2024-Q2 100% 83% 91% ALXO · PHVS · HRMY · SLRN · ELEV PHVS · ALXO · ALMS · HRMY · SLRN · ELEV
2024-Q3 83% 83% 83% PHVS · ALXO · ALMS · HRMY · SLRN · ELEV PHVS · ALMS · HRMY · ARTV · SLRN · ALXO
2024-Q4 100% 86% 92% PHVS · ALMS · ARTV · HRMY · SLRN · ALXO PHVS · ALMS · HRMY · ALXO · ARTV · SLRN · LYEL
2025-Q1 100% 100% 100% PHVS · ALMS · HRMY · ALXO · ARTV · SLRN · LYEL PHVS · ALMS · HRMY · SLRN · ALXO · LYEL · ARTV
2025-Q2 86% 100% 92% PHVS · ALMS · HRMY · SLRN · ALXO · LYEL · ARTV PHVS · HRMY · ALMS · LYEL · ALXO · ARTV
2025-Q3 100% 100% 100% PHVS · HRMY · ALMS · ALXO · LYEL · ARTV PHVS · ALMS · ALXO · HRMY · LYEL · ARTV
2025-Q4 100% 100% 100% PHVS · ALMS · ALXO · HRMY · LYEL · ARTV PHVS · ALMS · HRMY · ALXO · LYEL · ARTV
2026-Q1 100% 100% 100% PHVS · ALMS · HRMY · ALXO · LYEL · ARTV PHVS · ALMS · ALXO · HRMY · LYEL · ARTV
2026-Q2 ★ 83% 71% 77% PHVS · ALMS · ALXO · HRMY · LYEL · ARTV PHVS · PBLS · ALMS · ACHV · ALXO · HRMY · LYEL

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did venBio Partners LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, venBio Partners LLC reported 7 equity positions worth $519.38M in aggregate; its largest disclosed positions were PHVS ($160.57M), PBLS ($144.15M), ALMS ($127.43M).

How large is venBio Partners LLC's portfolio?

venBio Partners LLC reported $519.38M of long equity holdings across 7 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is venBio Partners LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/venbio-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →